SAB Biotherapeutics (SABS) Corporate presentation summary

Mission and strategic focus

• Aims to redefine Type 1 Diabetes (T1D) treatment by developing disease-modifying therapies that alter disease progression, not just symptoms.

• Focused on autoimmune T1D, leveraging a unique multi-specific antibody platform with high barriers to entry.

• Lead candidate SAB-142 targets newly diagnosed Stage 3 T1D, a multi-billion dollar global market.

• Platform generates fully human, multi-specific immunoglobulins without human donors using transchromosomic bovine technology.

• Backed by top-tier life science investors, with a cash runway through 2028.

SAB-142 product profile and clinical development

• SAB-142 is a fully human, multi-specific anti-thymocyte globulin (hATG) designed to delay T1D onset and progression by immunomodulating T cells and preserving C-peptide.

• Demonstrates a de-risked mechanism of action, comparable to rabbit ATG but with superior safety and redosing potential.

• Phase 1 data show no serum sickness, no anti-drug antibodies, and no sustained lymphodepletion, supporting chronic outpatient dosing.

• Phase 2b SAFEGUARD trial initiated in Q4 2025, targeting 159 patients aged 5-40, with topline data expected in 2H 2027.

• Clinical endpoints include C-peptide preservation, HbA1c, and glycemic control metrics.

Market opportunity and competitive landscape

• T1D affects ~9.5 million globally, with 64,000 new Stage 3 diagnoses annually in the US.

• Treatment landscape is evolving toward disease-modifying therapies, with a clear regulatory path established by Tzield.

• SAB-142 offers advantages over rATG and Tzield, including broader age range, superior safety, and more convenient dosing.

• Strategic partnerships include Breakthrough T1D (formerly JDRF) and Australasian Type 1 Diabetes Immunotherapy Collaborative.